Emcure buys remaining 12.05% in Gennova for Rs 231.87 crore

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

EMCURE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.2%Reaction day

₹1791.00

prior close

₹1789.70

announcement price

After-mkt

timing

Nifty Smallcap 250market-1.1%+2.3% vs market

Pharmaceuticals peers, median of 166sector-0.3%+1.4% vs sector

On the reaction day the stock moved 2.3 pts more than Nifty Smallcap 250 and 1.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.6

10m

+2.0

15m

+2.6

30m

+2.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.2-1.1+2.3-0.3+1.4

Next day

+0.1-0.4+0.5-0.3+0.3

+0.5-0.3+0.9-0.3+0.8

-0.4-0.9+0.6-1.3+1.0

+4.0-0.8+4.8-0.8+4.8

+7.8-0.4+8.2-0.7+8.5

+4.6-2.9+7.4-2.9+7.5

15d

+9.7+0.1+9.6-2.1+11.8

+7.6+0.6+7.1-0.9+8.6

+11.9-1.5+13.5-1.1+13.1

+3.9-1.9+5.7-2.7+6.6

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Emcure Pharmaceuticals is buying the remaining 12.05% stake (6,63,865 shares) in subsidiary Gennova Biopharmaceuticals for Rs 2,318.7 million in cash, making it a wholly-owned subsidiary. Gennova posted FY26 revenue of Rs 4,917.42 million and profit of Rs 54.25 million. Deal with related parties, done at arm's length. Completion expected by July 31, 2026.

Likely market impact

Consolidation move giving full control of biotech arm and simpler structure. Cash outflow of about Rs 232 crore, modest relative to Emcure's overall size.